Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET
Company Participants
Vince Anzalone – VP, IR
Chris Anzalone – President & CEO
Bruce Given – Interim Chief Medical Scientist
Andy Davis – SVP & Head of Global Cardiometabolic Franchise
James Hamilton – Chief Discovery & Translational Medicine
Ken Myszkowski – CFO
Conference Call Participants
Jasmine Fels – UBS
Luca Issi – RBC Capital
Andrea Newkirk – Goldman Sachs
Maury Raycroft – Jefferies
Dina Ramadane – Bank of America
Patrick Trucchio – H.C. Wainwright
Edward Tenthoff – PSC
Mayank Mamtani – B. Riley Securities
Prakhar Agrawal – Cantor
David Lebowitz – Citi
Keay Nakae – Chardan
Brendan Smith – TD Cowen
Mani Foroohar – Leerink
William Pickering – Bernstein
Operator
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today’s recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions.
I will now hand the conference over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, Vince.
Vince Anzalone
Thank you. Good afternoon, and thank you for joining us today to discuss Arrowhead’s results for its fiscal 2024 year-ended September 30, 2024. With us today from management are President and CEO, Dr. Chris Anzalone, who will provide an overview of the quarter; Dr. Bruce Given, Interim Chief Medical Scientist, who will provide an update on our cardiometabolic pipeline; Andy Davis, Senior Vice President and Head of Global Cardiometabolic Franchise, who will provide an update on commercialization activities; Dr. James Hamilton, Chief of Discovery and Translational Medicine, who will discuss our earlier-stage development programs; and Ken Myszkowski, Chief Financial Officer, who will give a review of the financials. We will then open the call to questions.
Before we begin, I
Credit: Source link
